Please assess the completion status of the following clinical trial:

Trial Title: Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women only: Must practice continuous effective contraception for the duration of the study.~* Agreement to refrain from blood donation during the course of the study and for at least 3 years after the end of their involvement in the study.~* Written informed consent to undergo CHMI.~* Reachable (24/7) by mobile phone during the whole study period.~* Willingness to take a curative anti-malaria regimen.~* For volunteers not living in Oxford: agreement to stay in a hotel room close to the trial centre during a part of the study (At least Day 6.5 post inoculation until 2 days after treatment commenced).~* Answer all questions on the informed consent quiz correctly.~Exclusion Criteria:~* History of clinical P. falciparum malaria.~* Travel to a malaria endemic region during the study period or within the preceding six months with positive P. falciparum serology at screening.~* Use of systemic antibiotics with known antimalarial activity within 30 days of study enrolment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin)~* Receipt of an investigational product in the 30 days preceding enrollment, or planned receipt during the study period.~* Prior receipt of an investigational malaria vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).~* Use of immunoglobulins or blood products within 3 months prior to enrollment.~* History of sickle cell anemia, sickle cell trait, thalassemia or thalassemia trait.~* Pregnancy, lactation or intention to become pregnant during the study~* A history of allergic disease or reactions likely to be exacerbated by malaria infection.~* Contraindications to the use of all three proposed anti-malarial medications; Malarone, Riamet and Chloroquine.~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).~* History of serious psychiatric condition that may affect participation in the study.~* Any other serious chronic illness requiring hospital specialist supervision.~* Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.~* Suspected or known injecting drug abuse in the 5 years preceding enrollment.~* Seropositive for hepatitis B surface antigen (HBsAg).~* Seropositive for hepatitis C virus (antibodies to HCV).~* An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system.39~* Positive family history in 1st and 2nd degree relatives \< 50 years old for cardiac disease.~* Volunteers unable to be closely followed for social, geographic or psychological reasons.~* Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.~* Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Plasmodium falciparum sporozoites 2sites (Type: EXPERIMENTAL): 2,500 sporozoites intradermally
- Plasmodium falciparum sporozoites 1 site (Type: EXPERIMENTAL): 2,500 sporozoites intramuscularly
- Plasmodium falciparum sporozoites 1site (Type: EXPERIMENTAL): 25,000 sporozoites intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).